Hackensack Meridian School of Medicine, Nutley, NJ, USA.
Hackensack University Medical Center, Hackensack, NJ, USA.
BMC Infect Dis. 2022 Mar 14;22(1):254. doi: 10.1186/s12879-022-07237-1.
Racial/ethnic minorities are at higher risk for severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic disparities with inflammatory markers and association of methylprednisolone to in hospital survival.
This was a secondary analysis of a retrospective cohort study of patients ≥ 18 years of age and admitted for severe COVID-19 pneumonia between March and June 2020 in 13 Hospitals in New Jersey, United States. Patients who received other formulation of corticosteroids were not included. Area under the receiver operating characteristics curves were performed to test for discriminatory ability of each inflammatory makers. Univariate and multivariate Cox regression assessed the association of variables to in hospital survival.
Propensity matched sample (n = 759) between no methylprednisolone (n = 380) and methylprednisolone (n = 379) had 338 Whites, 102 Blacks, 61 Asian/Indians, and 251 non-Black non-White Hispanics. Compared to CRP, area under receiving operating characteristic curve for d-dimer in Hispanics (0.742) was statistically different (DeLong Test P = 0.0041). Multivariate cox regression showed that different variables in Blacks [age ≥ 60 years (HR = 3.71, P = 0.0281), mechanical ventilation (HR = 5.07, P = 0.0281) and creatinine ≥ 1.5 mg/dL (HR = 3.61, P = 0.0007)], Whites [cancer (HR = 1.68, P = 0.0213), qSOFA score of 1 (HR = 1.81, P = 0.0213), qSOFA score of 2 (HR = 5.16, P < 0.0001), qSOFA score of 3 (HR = 11.81, P < 0.0001) and creatinine ≥ 1.5 mg/dL (HR = 2.16, P = 0.0006)], Hispanics [hypertension (HR = 2.52, P = 0.0007), cancer (HR = 2.99, P = 0.0244 and D-dimer ≥ 2 mcg/mL (HR = 2.22, P = 0.0077)], and Asian/Indians [ chronic kidney disease (HR = 6.36, P = 0.0031) and CRP > 20 mg/L (HR = 5.02, P = 0.0032)] were statistically significant for mortality. Low dose and high dose methylprednisolone were significantly associated with prolonged survival in Whites [low dose (HR = 0.37, P < 0.0001) and high dose (HR = 0.48, P < 0.0183)] and Asian/Indians [low dose (HR = 0.13, P = 0.0101) and high dose (HR = 0.15, P = 0.01)]. However, high dose was not associated with improved survival compared to low dose. Methylprednisolone was not associated with prolonged survival in Blacks and Hispanics.
Racial/Ethnic disparities with inflammatory markers preclude the use of one marker as a predictor of survival. Methylprednisolone is associated with prolonged survival in Asian/Indians and Whites.
少数民族/族裔群体患严重 COVID-19 的风险更高。这可能与导致慢性炎症状态的社会决定因素有关。本研究的目的是确定是否存在与炎症标志物相关的种族/族裔差异,以及甲基强的松龙与住院生存率的关系。
这是一项回顾性队列研究的二次分析,纳入了 2020 年 3 月至 6 月期间在美国新泽西州 13 家医院因严重 COVID-19 肺炎住院的年龄≥18 岁的患者。未包括接受其他皮质类固醇制剂的患者。进行了接受者操作特征曲线下面积的测试,以测试每个炎症标志物的区分能力。单变量和多变量 Cox 回归评估了变量与住院生存率的关系。
在未使用甲基强的松龙(n=380)和使用甲基强的松龙(n=379)的倾向匹配样本(n=759)中,有 338 名白人、102 名黑人、61 名亚洲/印度人、和 251 名非黑非白人西班牙裔。与 CRP 相比,西班牙裔人群中 D-二聚体的接受者操作特征曲线下面积(0.742)具有统计学差异(DeLong 检验 P=0.0041)。多变量 Cox 回归显示,黑人中不同的变量[年龄≥60 岁(HR=3.71,P=0.0281)、机械通气(HR=5.07,P=0.0281)和肌酐≥1.5mg/dL(HR=3.61,P=0.0007)]、白人[癌症(HR=1.68,P=0.0213)、qSOFA 评分 1(HR=1.81,P=0.0213)、qSOFA 评分 2(HR=5.16,P<0.0001)、qSOFA 评分 3(HR=11.81,P<0.0001)和肌酐≥1.5mg/dL(HR=2.16,P=0.0006)]、西班牙裔[高血压(HR=2.52,P=0.0007)、癌症(HR=2.99,P=0.0244)和 D-二聚体≥2mcg/mL(HR=2.22,P=0.0077)]和亚洲/印度裔[慢性肾脏病(HR=6.36,P=0.0031)和 CRP>20mg/L(HR=5.02,P=0.0032)]与死亡率具有统计学意义。低剂量和高剂量甲基强的松龙与白人[低剂量(HR=0.37,P<0.0001)和高剂量(HR=0.48,P<0.0183)]和亚洲/印度裔[低剂量(HR=0.13,P=0.0101)和高剂量(HR=0.15,P=0.01)]的生存时间延长显著相关。然而,与低剂量相比,高剂量与生存改善无关。甲基强的松龙与黑人及西班牙裔患者的生存时间延长无关。
炎症标志物与种族/族裔差异使得不能使用单一标志物作为生存预测因子。甲基强的松龙与亚洲/印度裔和白人的生存时间延长有关。